BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Solve ME/CFS Initiative - ECPv6.15.17//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Solve ME/CFS Initiative
X-ORIGINAL-URL:https://solvecfs.org
X-WR-CALDESC:Events for Solve ME/CFS Initiative
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260714T150000
DTEND;TZID=America/Los_Angeles:20260714T160000
DTSTAMP:20260710T032358
CREATED:20260622T155750Z
LAST-MODIFIED:20260622T155750Z
UID:44319-1784041200-1784044800@solvecfs.org
SUMMARY:Repurposing Rapamycin: A Report On the First Biomarker-Driven Treatment Trial for ME/CFS
DESCRIPTION:In 2025\, Simmaron Research was the second recipient of Solve’s ME/CFS Catalyst Award in support of its study\, “Low Dose Rapamycin in ME/CFS\, Long-COVID\, and Other Infection-Associated Chronic Conditions.” The study hypothesizes that mTOR inhibition through rapamycin may address observed findings of autophagy impairment and symptoms in a subset of patients with ME/CFS and other infection-associated chronic conditions and illnesses (IACCIs).   \nThe study advances an already FDA-approved drug for reducing key symptoms of ME/CFS and Long Covid\, repurposing rapamycin to reduce fatigue\, orthostatic intolerance\, post-exertional malaise\, and sleep issues for a subset of people with ME/CFS. \nIn this webinar hosted by Solve M.E. President Emily Taylor\, panelists Courtney Miller (Board President at Simmaron)\, Dr. C. Gunnar Gottschalk (Chief Executive Officer at Simmaron)\, and Dr. Avik Roy (Chief Scientific Officer at Simmaron) will discuss the latest learnings from the study\, and their plan to conduct an  NIH exploratory treatment trial based on the data. 
URL:https://solvecfs.org/event/repurposing-rapamycin-a-report-on-the-first-biomarker-driven-treatment-trial-for-me-cfs/
CATEGORIES:Long Covid,Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2026/06/July14SimmaronWebinar2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260908T150000
DTEND;TZID=America/Los_Angeles:20260908T160000
DTSTAMP:20260710T032358
CREATED:20260512T140700Z
LAST-MODIFIED:20260512T140700Z
UID:43935-1788879600-1788883200@solvecfs.org
SUMMARY:A Safe\, Accessible Treatment for ME/CFS? The Mitochondrial Stabilizer IVO-21 Study
DESCRIPTION:As part of our commitment to advancing science that brings real hope to people living with ME/CFS or Long Covid\, Solve has selected Dr. Jay H. Chung (National Institutes of Health) as a recipient of our latest ME/CFS Catalyst Award. \nDr. Chung’s groundbreaking study\, “Mitochondrial Stabilizer IVO-21 As Therapy for ME/CFS\,” is focused on developing a new way to restore cellular energy production by targeting two of the most debilitating and poorly treated aspects of ME/CFS and Long Covid—mitochondrial dysfunction and chronic inflammation—mechanisms believed to drive symptoms such as fatigue and brain fog. \nThe compound at the heart of this study is IVO\, an inexpensive small-molecule therapy that can be easily taken as pills. Early results in cell-culture models suggest IVO restores mitochondrial energy production and reduces systemic inflammation. The next step is to evaluate how well IVO alleviates sickness behavior in preclinical (mouse) models. \nIn this free educational webinar hosted by Solve Vice President of Scientific Programs Dr. Jessica Maya\, Dr. Chung will explain why his research is an essential step toward future clinical studies that could benefit millions and how it could pave the way for a safe\, accessible treatment that addresses the root causes of these complex diseases. \nRegister here.
URL:https://solvecfs.org/event/a-safe-accessible-treatment-for-me-cfs-the-mitochondrial-stabilizer-ivo-21-study/
CATEGORIES:Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2026/05/Sept8DrChung.png
END:VEVENT
END:VCALENDAR